Evidence map›Paper›PMID 33781277›Full record

ArticleJournal of nanobiotechnology2021

Targeting triple-negative breast cancer with an aptamer-functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies.

Yi-Te Chou, Chih-Yu Lin, Jyun-Wei Wen, Ling-Chun Hung, Ying-Feng Chang, Chia-Min Yang, Li-Chen Wu, Ja-An Annie Ho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Innovative strategies for photodynamic therapy against hypoxic tumor.Asian journal of pharmaceutical sciences · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yi-Te Chou *BioAnalytical Chemistry and Nanobiomedicine Laboratory, Department of Biochemical Science and Technology, National Taiwan University, Taipei, 10617, Taiwan.
Chih-Yu Lin *Department of Chemistry, National Tsing Hua University, Hsinchu, 30013, Taiwan.
Jyun-Wei Wen *BioAnalytical Chemistry and Nanobiomedicine Laboratory, Department of Biochemical Science and Technology, National Taiwan University, Taipei, 10617, Taiwan.
Ling-Chun HungBioAnalytical Chemistry and Nanobiomedicine Laboratory, Department of Biochemical Science and Technology, National Taiwan University, Taipei, 10617, Taiwan.
Ying-Feng ChangBioAnalytical Chemistry and Nanobiomedicine Laboratory, Department of Biochemical Science and Technology, National Taiwan University, Taipei, 10617, Taiwan.
Chia-Min YangDepartment of Chemistry, National Tsing Hua University, Hsinchu, 30013, Taiwan. cmyang@mx.nthu.edu.tw.
Li-Chen WuDepartment of Applied Chemistry, National Chi Nan University, Puli, Nantou, 54561, Taiwan. lw25@ncnu.edu.tw.
Ja-An Annie HoBioAnalytical Chemistry and Nanobiomedicine Laboratory, Department of Biochemical Science and Technology, National Taiwan University, Taipei, 10617, Taiwan. jaho@ntu.edu.tw.ORCID http://orcid.org/0000-0001-6684-1118
National Taiwan University · TWNational Tsing Hua University · TWNational Chi Nan University · TWNational Taiwan University of Science and Technology · TW

Funding

Ministry of Science and Technology, Taiwan 106-2113-M-002-014-MY3Ministry of Science and Technology, Taiwan 106-2113-M-007-025-MY3Ministry of Science and Technology, Taiwan 107-3017-F-007-002Ministry of Science and Technology, Taiwan MOST 102-2628-M-002-004-MY4Ministry of Science and Technology, Taiwan MOST 107-2113-M-260-002-MY2
6 · The paper itself

Abstract

backgroundAreas of hypoxia are often found in triple-negative breast cancer (TNBC), it is thus more difficult to treat than other types of breast cancer, and may require combination therapies. A new strategy that combined bioreductive therapy with photodynamic therapy (PDT) was developed herein to improve the efficacy of cancer treatment. Our design utilized the characteristics of protoporphyrin IX (PpIX) molecules that reacted and consumed O

resultsTo achieve the co-delivery of PpIX and TPZ for advanced breast cancer therapy, thin-shell hollow mesoporous Ia3d silica nanoparticles, designated as MMT-2, was employed herein. This nanocarrier designed to target the human breast cancer cell MDA-MB-231 was functionalized with PpIX and DNA aptamer (LXL-1), and loaded with TPZ, resulting in the formation of TPZ@LXL-1-PpIX-MMT-2 nanoVector. A series of studies confirmed that our nanoVectors (TPZ@LXL-1-PpIX-MMT-2) facilitated in vitro and in vivo targeting, and significantly reduced tumor volume in a xenograft mouse model. Histological analysis also revealed that this nanoVector killed tumor cells in hypoxic regions efficiently.

conclusionsTaken together, the synergism and efficacy of this new therapeutic design was confirmed. Therefore, we concluded that this new therapeutic strategy, which exploited a complementary combination of PpIX and TPZ, functioned well in both normoxia and hypoxia, and is a promising medical procedure for effective treatment of TNBC.

Indexed as

AnimalsAntineoplastic AgentsAptamers, NucleotideCell Line, TumorCombined Modality TherapyFemaleHumansMiceNanoparticlesOxygenPhotochemotherapyProdrugsReactive Oxygen SpeciesSilicon DioxideTirapazamineTriple Negative Breast NeoplasmsAntineoplastic AgentsAptamers, NucleotideOxygenProdrugsReactive Oxygen SpeciesSilicon DioxideTirapazamineBioreductive prodrugDNA aptamerHollow mesoporous silica nanoparticlePhotodynamic therapyTriple‐negative breast cancerTumor hypoxia

Identifiers

PMID33781277
PMCPMC8008604
OpenAlexW3147183144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.